PDF(Pubmed)
Abstract：
UNASSIGNED: In this study, we present our minimally invasive Ivor-Lewis esophagectomy technique and survival rates of this technique.
UNASSIGNED: Between September 2013 and December 2020, a total of 140 patients (56 males, 84 females; mean age: 55.5±10.3 years; range, 32 to 76 years) who underwent minimally invasive Ivor- Lewis esophagectomy for esophageal cancer were retrospectively analyzed. Preoperative patient data, oncological and surgical outcomes, pathological results, and complications were recorded.
UNASSIGNED: Primary diagnosis was esophageal cancer in all cases. Minimally invasive Ivor-Lewis esophagectomy was carried out in all of the cases included in the study. Neoadjuvant chemoradiotherapy was administrated in 97 (69.3%) of the cases. The mean duration of surgery was 261.7±30.6 (range, 195 to 330) min. The mean amount of intraoperative blood loss was 115.1±190.7 (range, 10 to 800) mL. In 60 (42.9%) of the cases, complications occurred in intraoperative and early-late postoperative periods. The anastomotic leak rate was 7.1% and the pulmonary complication rate was 22.1% in postoperative complications. The mean hospital stay length was 10.6±8.4 (range, 5-59) days and hospital mortality rate was 2.1%. The median follow-up duration was 37 (range, 2-74) months and the three- and five-year overall survival rates were 61.8% and 54.6%, respectively.
UNASSIGNED: Minimally invasive Ivor-Lewis esophagectomy can be used safely with low mortality and long-time survival rates in esophageal cancer.
UNASSIGNED: Between September 2013 and December 2020, a total of 140 patients (56 males, 84 females; mean age: 55.5±10.3 years; range, 32 to 76 years) who underwent minimally invasive Ivor- Lewis esophagectomy for esophageal cancer were retrospectively analyzed. Preoperative patient data, oncological and surgical outcomes, pathological results, and complications were recorded.
UNASSIGNED: Primary diagnosis was esophageal cancer in all cases. Minimally invasive Ivor-Lewis esophagectomy was carried out in all of the cases included in the study. Neoadjuvant chemoradiotherapy was administrated in 97 (69.3%) of the cases. The mean duration of surgery was 261.7±30.6 (range, 195 to 330) min. The mean amount of intraoperative blood loss was 115.1±190.7 (range, 10 to 800) mL. In 60 (42.9%) of the cases, complications occurred in intraoperative and early-late postoperative periods. The anastomotic leak rate was 7.1% and the pulmonary complication rate was 22.1% in postoperative complications. The mean hospital stay length was 10.6±8.4 (range, 5-59) days and hospital mortality rate was 2.1%. The median follow-up duration was 37 (range, 2-74) months and the three- and five-year overall survival rates were 61.8% and 54.6%, respectively.
UNASSIGNED: Minimally invasive Ivor-Lewis esophagectomy can be used safely with low mortality and long-time survival rates in esophageal cancer.
摘要：
未经批准：在这项研究中，我们介绍了我们的微创Ivor-Lewis食管切除术技术和该技术的生存率。
UNASISIGNED：2013年9月至2020年12月期间，共有140名患者（56名男性，84名女性；平均年龄：55.5±10.3岁；范围，对32至76岁）接受微创Ivor-Lewis食管癌切除术的患者进行回顾性分析。术前患者数据,肿瘤和手术结果，病理结果,并记录并发症。
UNASSIGNED：所有病例的主要诊断均为食管癌。在研究中包括的所有病例中都进行了微创Ivor-Lewis食管切除术。97例（69.3％）进行了新辅助放化疗。平均手术时间为261.7±30.6（范围，195至330）分钟。术中平均失血量为115.1±190.7(范围，10～800)mL。在60例(42.9%)中，并发症发生在术中和术后早期至晚期。术后并发症中吻合口漏发生率为7.1%,肺部并发症发生率为22.1%。平均住院时间为10.6±8.4(范围，5-59）天，住院死亡率为2.1％。中位随访时间为37(范围，2-74）个月和3年和5年总生存率分别为61.8％和54.6％，分别。
UNASSIGNED：微创Ivor-Lewis食管癌切除术可安全使用，死亡率低，长期生存率高。
UNASISIGNED：2013年9月至2020年12月期间，共有140名患者（56名男性，84名女性；平均年龄：55.5±10.3岁；范围，对32至76岁）接受微创Ivor-Lewis食管癌切除术的患者进行回顾性分析。术前患者数据,肿瘤和手术结果，病理结果,并记录并发症。
UNASSIGNED：所有病例的主要诊断均为食管癌。在研究中包括的所有病例中都进行了微创Ivor-Lewis食管切除术。97例（69.3％）进行了新辅助放化疗。平均手术时间为261.7±30.6（范围，195至330）分钟。术中平均失血量为115.1±190.7(范围，10～800)mL。在60例(42.9%)中，并发症发生在术中和术后早期至晚期。术后并发症中吻合口漏发生率为7.1%,肺部并发症发生率为22.1%。平均住院时间为10.6±8.4(范围，5-59）天，住院死亡率为2.1％。中位随访时间为37(范围，2-74）个月和3年和5年总生存率分别为61.8％和54.6％，分别。
UNASSIGNED：微创Ivor-Lewis食管癌切除术可安全使用，死亡率低，长期生存率高。
